| Literature DB >> 24790622 |
Teresa Garcia-Martinez1, Jan-Pieter Chan2, Jose Perez-Calatayud3, Facundo Ballester4.
Abstract
PURPOSE: Brachytherapy with radioactive high dose rate (HDR) (192)Ir source is applied to small skin cancer lesions, using surface applicators, i.e. Leipzig or Valencia type. New developments in the field of radiotherapy for skin cancer include electronic brachytherapy. This technique involves the placement of an HDR X-ray source close to the skin, therefore combining the benefits of brachytherapy with the reduced shielding requirements and targeted energy of low energy X-rays. Recently, the Esteya(®) Electronic Brachytherapy System (Esteya EBS, Elekta AB-Nucletron, Stockholm, Sweden) has been developed specifically for HDR brachytherapy treatment of surface lesions. The system provides radionuclide free HDR brachytherapy by means of a small 69.5 kV X-ray source. The purpose of this study is to obtain the dosimetric characterization required for clinical implementation, providing the detailed methodology to perform the commissioning.Entities:
Keywords: electronic brachytherapy; nonmelanoma skin-cancer; skin brachytherapy; superficial radiotherapy
Year: 2014 PMID: 24790622 PMCID: PMC4003426 DOI: 10.5114/jcb.2014.40770
Source DB: PubMed Journal: J Contemp Brachytherapy ISSN: 2081-2841
Fig. 1The Esteya Electronic Brachytherapy System
Fig. 2Schematic view of the spectrum measurement setup
Fig. 3Schematic representation of the setup for the leakage evaluation
Flatness and symmetry results of the Esteya unit results for all available surface applicators. Uncertainties are given with a coverage factor k = 1
| Surface applicator diameter [mm] | Flatness | Symmetry | ||
|---|---|---|---|---|
| GT | AB | GT | AB | |
| 30 | 4.3 ± 0.3% | 2.8 ± 0.1% | 104.8 ± 0.5% | 96.6 ± 0.3% |
| 25 | 3.7 ± 0.8% | 3.0 ± 2.3% | 104.6 ± 0.6% | 94.1 ± 2.7% |
| 20 | 3.4 ± 0.6% | 3.5 ± 0.5% | 103.3 ± 0.8% | 97.2 ± 0.8% |
| 15 | 4.4 ± 0.1% | 4.6 ± 1.2% | 103.4 ± 0.4% | 95.9 ± 3.1% |
| 10 | 6.9 ± 1.0% | 7.4 ± 1.6% | 106.0 ± 1.4% | 99.0 ± 9.5% |
Penumbra evaluation results for all available surface applicators. Uncertainties are given with a coverage factor k = 1
| Surface applicator diameter [mm] | Direction penumbra [mm] | |||
|---|---|---|---|---|
| G | T | A | B | |
| 30 | 0.88 ± 0.02 | 0.98 ± 0.04 | 1.10 ± 0.09 | 1.14 ± 0.07 |
| 25 | 1.15 ± 0.01 | 1.25 ± 0.04 | 1.30 ± 0.01 | 1.31 ± 0.01 |
| 20 | 1.04 ± 0.06 | 1.10 ± 0.05 | 1.27 ± 0.04 | 1.22 ± 0.03 |
| 15 | 0.97 ± 0.03 | 1.05 ± 0.06 | 1.12 ± 0.15 | 1.12 ± 0.02 |
| 10 | 0.86 ± 0.01 | 0.87 ± 0.18 | 1.06 ± 0.10 | 0.99 ± 0.15 |
PDD data for each surface applicator size normalized to the maximum value at 0 mm
| Depth [mm] | Surface applicator diameter [mm] | ||||
|---|---|---|---|---|---|
| 10 | 15 | 20 | 25 | 30 | |
| 0 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| 1 | 92.7% | 92.3% | 92.4% | 92.4% | 92.5% |
| 2 | 87.6% | 85.9% | 86.2% | 86.3% | 86.5% |
| 3 | 80.1% | 80.6% | 80.4% | 81.0% | 81.0% |
| 4 | 73.1% | 74.4% | 74.6% | 75.5% | 75.8% |
| 5 | 68.6% | 69.9% | 70.9% | 71.3% | 71.7% |
| 6 | 63.8% | 65.0% | 65.8% | 67.0% | 67.4% |
| 7 | 59.1% | 60.7% | 61.8% | 62.6% | 62.9% |
| 8 | 55.9% | 57.0% | 57.9% | 58.4% | 59.0% |
| 9 | 51.7% | 52.5% | 54.3% | 55.1% | 55.3% |
| 10 | 48.5% | 50.0% | 51.3% | 52.2% | 52.7% |
Absolute dose rate values and its standard deviation (k = 1) at 0 mm depth for the five surface applicators
| Applicator diameter [mm] | Dose rate at 0 mm depth |
|---|---|
| 10 | 3.004 ± 0.013 |
| 15 | 3.122 ± 0.001 |
| 20 | 3.197 ± 0.002 |
| 25 | 3.300 ± 0.001 |
| 30 | 3.295 ± 0.001 |
Fig. 4Esteya electronic brachytherapy system spectrum
Fig. 530 mm applicator central axis depth dose normalized @ 3 mm
Fig. 6Half profiles at 5 mm depth normalized to the central axis value for the 30 mm in diameter applicators